These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11712625)

  • 21. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical efficacy of citalopram in patients with obsessive-compulsive disorder].
    Jakitowicz J; Nowicki Z; Wiśniewski G
    Psychiatr Pol; 2002; 36(6 Suppl):297-301. PubMed ID: 12647452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical predictors of drug response in obsessive-compulsive disorder.
    Erzegovesi S; Cavallini MC; Cavedini P; Diaferia G; Locatelli M; Bellodi L
    J Clin Psychopharmacol; 2001 Oct; 21(5):488-92. PubMed ID: 11593074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Intravenous Citalopram on the Neural Substrates of Obsessive-Compulsive Disorder.
    Bhikram TP; Farb NA; Ravindran LN; Papadopoulos YG; Conn DK; Pollock BG; Ravindran AV
    J Neuropsychiatry Clin Neurosci; 2016; 28(3):243-7. PubMed ID: 27019066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder.
    Jang JH; Kwon JS; Jang DP; Moon WJ; Lee JM; Ha TH; Chung EC; Kim IY; Kim SI
    Am J Psychiatry; 2006 Jul; 163(7):1202-7. PubMed ID: 16816225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escitalopram in the treatment of obsessive-compulsive disorder.
    Zohar J
    Expert Rev Neurother; 2008 Mar; 8(3):339-49. PubMed ID: 18345966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Hollander E; Kaplan A; Schmeidler J; Yang H; Li D; Koran LM; Barbato LM
    J Neuropsychiatry Clin Neurosci; 2005; 17(4):472-7. PubMed ID: 16387985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
    Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
    CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Bruno A; Micò U; Pandolfo G; Mallamace D; Abenavoli E; Di Nardo F; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
    J Psychopharmacol; 2012 Nov; 26(11):1456-62. PubMed ID: 22351381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.